TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05970718
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for single ascending IV or SC administration per the protocol
Study: NCT05605756
Drug: OnabotulinumtoxinA 145 UNT [Botox]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum A toxin injection: Will follow the FDA-approved guideline of the treatment of chronic migraine. The following modifications are planned: (a) Total units 145 instead of 155. (b) Number of injection sites 29 instead of 31. (c) the 6 injection sites in the trapezius muscle will be eliminated as they are irrelevant to our attempt to reduce seizure events. Instead, 4 injections will be made subcutaneously along the superior sagittal suture (see figures below), where no muscles exist and thus no muscle weakness is likely. This dose (145 Units) is well below the FDA-approved guideline on safety for adolescents and adults (no more than 10 Units/Kg or a total of 340 Units).~Botox injections will take place in the BIDMC Headache Clinic which is a part of the Arnold Pain center at 1 Brookline Place. Injections will be administered by Dr. Sait Ashina, the Director of the Headache Clinic.
Study: NCT06189495
Drug: GenSci048
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Dosage: 300 mg.2. Duration of administration: All subjects received one dose of Genakumab injection every 4 weeks according to their group.The dose was injected subcutaneously.3. Course of administration: Phase I subjects were treated with Genakumab injection until the end of the study or the occurrence of the drug.Tolerable toxicity or investigator-assessed efficacy (whichever occurs first); The phase 2 randomized double-blind treatment period was 24 weeks, with a total of 6 administration times. After the randomized double-blind treatment period, an open-label treatment period was entered, and all subjects will receive Genakumab injection 300 mg Q4W until the end of the study or the occurrence of intolerable toxicity or poor efficacy assessed by the investigators (whichever occurs first).4. Administration method: subcutaneous injection; The injection site is the abdomen (3 cm away from the navel
Study: NCT06189495
Drug: GenSci048 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Dosage: 300 mg.2. Duration of administration: All subjects received one dose of placebo every 4 weeks according to their group The dose was injected subcutaneously.3. Course of administration: Phase I subjects were treated with placebo until the end of the study or the occurrence of the drug.Tolerable toxicity or investigator-assessed efficacy (whichever occurs first); The phase 2 randomized double-blind treatment period was 24 weeks, with a total of 6 administration times. After the randomized double-blind treatment period, an open-label treatment period was entered, and all subjects will receive placebo 300 mg Q4W until the end of the study or the occurrence of intolerable toxicity or poor efficacy assessed by the investigators (whichever occurs first).~4. Administration method: subcutaneous injection; The injection site is the abdomen (3 cm away from the navel)
Study: NCT06074562
Drug: LY3556050
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05723640
Drug: 177Lu-LNC1004 Injection group 4 radionuclide therapy
Normalized name: Zostrix Cold Therapy 4 % Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment regimen will consist of a single dose 100mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
Study: NCT05688852
Drug: VTX958
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose B VTX958
Study: NCT05688852
Drug: VTX958 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04979572
Drug: TS-172
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Single doses of TS-172 10 mg, 30 mg, 90 mg, 270 mg before breakfast in each period (only 30 mg administered before breakfast and fasting)~* Multiple dose of TS-172 90 mg before breakfast and dinner
Study: NCT04979572
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Single doses of TS-172 placebo before breakfast in each period (only placebo administered before breakfast and fasting in step 2)~* Multiple dose of TS-172 placebo before breakfast and dinner
Study: NCT04512716
Drug: 131-I Apamistamab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 131-I apamistamab 5-7 days prior to a single infusion of 1x10\^6 19-28z CAR T-cells/kg for those in the B-ALL cohort, or 2x10\^6 19-28z CAR T-cells/kg, for those in the DLBCL. 131-I apamistamab may be administered inpatient or outpatient at the discretion and judgment of the treating investigators.
Study: NCT06011577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT05745727
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of Placebo will be given in different cohorts i.e., Cohorts 1 through 8
Study: NCT06364800
Drug: targeted drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-target kinase inhibitors can act on VEGFR-1,VEGFR-2,VEGFR-3,FGFR1,PDGFR,cKit,Ret and other targets.
Study: NCT05617820
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal Insert, 4 mcg tablet
Study: NCT05617820
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Vaginal Insert
Study: NCT06558253
Drug: Coenzyme I for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received 21 consecutive days of intravenous infusion of Coenzyme I for injection, starting from the day of transplantation , and then continuously applied intravenously until 20 days post transplantation, with three dose groups: subjects #1-3 received one intravenous infusion per day containing 10 mg of Coenzyme I for injection, subjects #4-6 received one intravenous infusion per day containing 20 mg of Coenzyme I for injection, and subjects #7-12 received one intravenous infusion per day containing 50 mg of Coenzyme I for injection. Subjects in either dose group experienced a treatment-related Grade 3 or higher adverse reaction, the previous dose group was the maximum tolerated dose.
Study: NCT04964934
Drug: AZD9833
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage formulation: AZD9833 tablets will be administered orally
Study: NCT04964934
Drug: AZD9833 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage formulation: AZD9833 placebo tablets will be administrated orally.
Study: NCT06276231
Drug: Diclofenac Injection
Normalized name: diclofenac Injection
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 75 mg of Diclofenac intramuscular Injection
Study: NCT04834557
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered to the control group for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
Study: NCT05630755
Drug: DOR/ISL
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOR/ISL 100 mg/0.25 mg oral tablets once daily
Study: NCT05630755
Drug: BIC/FTC/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIC/FTC/TAF 50 mg/200 mg/25 mg oral tablets once daily
Study: NCT05630755
Drug: Placebo to BIC/FTC/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg oral tablets once daily
Study: NCT05630755
Drug: Placebo to DOR/ISL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg oral tablets once daily
Study: NCT04334759
Drug: Standard Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks) for 4 to 6 cycles, followed by Observation
Study: NCT05115942
Drug: The placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: After randomization, The control group were orally received placebo capsules at a daily dose of 270 mg, 3 capsules each time, t.i.d, 30 min before meals for 52 weeks.
Study: NCT05005078
Drug: WST-057
Approvals — FDA: no, EMA: no, PMDA: no
Description: WST-057 topical solution
Study: NCT05005078
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: WST-057 Matching placebo
Study: NCT05504395
Drug: CSTI-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 10 mg capsule
Study: NCT05216614
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactose placebo capsules identical to fluvoxamine capsules in order to preserve blind
Study: NCT06432764
Drug: AZD7798
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participating patient will receive the study drug as specified in the study protocol.
Study: NCT04998006
Drug: Alcohol and Cannabis vs. Alcohol only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-directed (ad-libitum) cannabis and alcohol vs. self-direct (ad-libitum) alcohol
Study: NCT05085548
Drug: ProAgio Dose Levels (DL) 4,5,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProAgio is administered to study participants by intravenous injections once every 7 days.
Study: NCT06419621
Drug: PM8002
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM8002 20 mg/kg via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle
Study: NCT06419621
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 20 mg/kg via IV infusion on Days 1 and 15 of each 28-day cycle
Study: NCT06229678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be administered orally once per day for 3 months
Study: NCT06653296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six weeks of placebo in capsule form taken orally once daily in the evening for a 6-week total treatment period
Study: NCT05835206
Drug: Microbiome Therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single course of study treatment (IP, Encapsulated Microbiota): Orally delivered, non-frozen, encapsulated investigational intestinal microbiota, consisting of 16 capsules. One dose (8 capsules) is administered daily (QD) for 2 days. The capsules are to be taken orally with water on an empty stomach. Each dose will be taken approximately every 24 hours, with a minimum of 12 hours from the previous dose to a maximum of 36 hours. Both doses must be completed within the stated 36 hours ±12 hours. Depending on the time of the first dose, dosing may occur over 3 calendar days.~A second cycle will begin and a second treatment will be given if the participant is still MDRO positive on Day 14 of Cycle 1. If applicable, Cycle 2 will begin within 7 days of Day 14.
Study: NCT05835206
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single course of study treatment (Color-matched placebo capsules containing microcrystalline cellulose (MCC) powder), consisting of 16 capsules. One dose (8 capsules) is administered daily (QD) for 2 days. The capsules are to be taken orally with water on an empty stomach. Each dose will be taken approximately every 24 hours, with a minimum of 12 hours from the previous dose to a maximum of 36 hours. Both doses must be completed within the stated 36 hours ±12 hours. Depending on the time of the first dose, dosing may occur over 3 calendar days.~A second cycle will begin and a second treatment will be given if the participant is still MDRO positive on Day 14 of Cycle 1. If applicable, Cycle 2 will begin within 7 days of Day 14.
Study: NCT06332781
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administered via bladder
Study: NCT05613166
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C
Study: NCT04574778
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of oral acetaminophen preoperatively administered
Study: NCT06624670
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone
Study: NCT06259981
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 placebo capsules orally twice daily
Study: NCT06481488
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2086 matched placebo tablets.
Study: NCT04790305
Drug: Huaier Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects in the experimental group will be treated with Huaier Granule continuously for 2 years or until the disease progressed, intolerable toxicity, withdrawal of informed consent form or died for any reason.
Study: NCT04649476
Drug: Camrelizumanb plus TPF
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive camrelizumab (200 mg) through intravenous infusion each 2-week cycle, and docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2, 5-Fluorouracil (F) 750 mg/m2 through intravenous infusion each 3-week cycle for 2 cycles.
Study: NCT05741372
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin
Study: NCT05570383
Drug: Dust mite drops (trade name: Changdi, Zhejiang Tawu Biotechnology Co. Ltd.).
Approvals — FDA: no, EMA: no, PMDA: no
Description: The experimental group will be with Sublingual immunotherapy (trade name: Changdi, Zhejiang Tawu Biotechnology Co., Ltd.). The control group will be with Mometasone Furoate Aqueous Nasal Spray (NASUNA); The treatment course of the two groups will be 3 months.
Study: NCT05164250
Drug: REGN5458
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05220917
Drug: 2nd generation SU
Normalized name: SUS SCROFA EYE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any 2nd generation SU claim
Study: NCT05045157
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: corticosteroid injection is performed
Study: NCT04680026
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline
Study: NCT06366711
Drug: Pulsenmore device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote ultrasound device for pregnancy care
Study: NCT06379685
Drug: Systane Ultra®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propylene glycol 0.3% - Polyethylene glycol 400 0.4%. Ophthalmic solution.
Study: NCT04579848
Drug: Methotrexate Tablets
Normalized name: Methotrexate Tablets
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 2.5mg oral tablet.
Study: NCT04579848
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT04579848
Drug: Folic Acid 1 MG
Normalized name: folic acid 1 MG
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid
Study: NCT06683911
Drug: non Opioids
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is planned to avoid opioid side effects by applying opioid-free anesthesia during the perioperative period.
Study: NCT06683911
Drug: Opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine general anesthesia in cardiac surgery
Study: NCT06518122
Drug: HCP1306
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once a day per period.
Study: NCT06518122
Drug: RLD2302
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once a day per period.
Study: NCT06518122
Drug: RLD2102
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once a day per period
Study: NCT04925752
Drug: Placebo SC LEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via SC injections
Study: NCT04925752
Drug: PTM F/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT04925752
Drug: F/TAF (for US participants only)
Approvals — FDA: no, EMA: no, PMDA: no
Description: F/TAF tablets administered orally once daily
Study: NCT05139810
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donidalorsen-matching placebo was administered by SC injection.
Study: NCT06007352
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be given 120 mg of gentamicin infused in 3 L NaCl used in irrigation for ureteroscopy
Study: NCT06636357
Drug: 50% N2O plus 50% O2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 50% N2O plus 50% O2 for 45 min
Study: NCT06680375
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered.
Study: NCT06269705
Drug: TCA-IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA injection of 40 mg TCA-IR
Study: NCT05260411
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered placebo by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
Study: NCT04931628
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl
Study: NCT06151392
Drug: Probiotic Formula
Normalized name: Probiotic Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: probiotic will be administered to pediatric patients with ventriculitis to study their possible effect in treatment
Study: NCT06151392
Drug: Zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc will be administered to pediatric patients with ventriculitis to study their possible effect in treatment
Study: NCT06019507
Drug: TAC
Normalized name: TAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppression Therapy
Study: NCT06019507
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppression Therapy
Study: NCT05039450
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06597760
Drug: Enlicitide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 20 mg enlicitide/180 mg sodium caprate coadministered with 0.25mg Digoxin orally on Day 1, Period 2 in Arm A and on Day 1 Period 1 in Arm B.
Study: NCT04738812
Drug: Intensified TB treatment (initial phase)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 weeks of RHEZ with high dose of rifampicin (R) and isoniazid (H). Fixed dose combination (FDC) of RHZE with the addition of FDC of RH and single caps of R.~6 weeks of prednisone with tapering doses. 3 days of albendazole 400 mg.
Study: NCT05517928
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules daily that look exactly like the study drug, but contains to active ingredient
Study: NCT03883945
Drug: AIV001
Approvals — FDA: no, EMA: no, PMDA: no
Description: intradermal injection
Study: NCT03883945
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: intradermal injection
Study: NCT06201624
Drug: Triple combination formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are instructed to apply the triple combination formula at night daily for 3 months
Study: NCT06358313
Drug: Rosuvastatin 20mg
Normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The rosuvastatin group consisted of 300 patients who received 40 mg daily rosuvastatin for 3 months, an open-label aspirin at a loading dose of 75 to 300 mg, and then 75 mg daily till the end of the 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
Study: NCT05007470
Drug: VSL #3 112.5 Capsule
Normalized name: VSL #3 112.5 Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: VSL#3 is a commercial probiotic mixture consisting of eight bacterial strains: Four strains of Lactobacillus (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus delbrueckii subspecies bulgaricus), three strains of Bifidobacterium (Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis), and one strain of Streptococcus (Streptococcus salivarius subspecies thermophilus).
Study: NCT06052852
Drug: BDC-3042
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dectin-2 agonist antibody
Study: NCT04826588
Drug: Methylprednisolone sodium succinate 10 mg/kg intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone sodium succinate 10 mg/kg intravenously once daily for 3 days (max 1 g per dose)
Study: NCT06256484
Drug: ATA3219
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATA3219 is allogeneic anti-CD19 chimeric antigen receptor T-cell, administered intravenously on Day 1.
Study: NCT06185985
Drug: SPN-812
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPN-812 (200mg to 600mg once daily)
Study: NCT05776459
Drug: AC102 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: AC102 Single intratympanic injection
Study: NCT05776459
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active comparator: Prednisolone Tablets taken daily by mouth
Study: NCT05494593
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive 0.4 mg/kg of methotrexate by mouth (PO) 3 times per week for 5 weeks in each cycle.
Study: NCT06679998
Drug: Single dose, AAPB by injection, intravenous drip.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received a single intravenous infusion of AAPB for injection. Each dose of AAPB for injection was dissolved with 0.9% sodium chloride injection, the infusion volume was 100mL, once a day, and each time was continuously injected for 60 min±5min.
Study: NCT06679998
Drug: Multiple dosing, AAPB for injection, intravenous drip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received AAPB for injection with multiple intravenous drips. Each dose of AAPB for injection was dissolved with 0.9% sodium chloride injection, the infusion volume was 100mL, once a day, 60 min±5min each time, for 7 consecutive days.
Study: NCT04271436
Drug: [F-18] flurothymidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: -Radiopharmaceutical
Study: NCT05442983
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT06680752
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: iv administration for lymphodepletion
Study: NCT05511922
Drug: KVD900 600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: KVD900 Tablet 600 mg (2 x 300 mg)
Study: NCT05511922
Drug: Drug: KVD900 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: KVD900 Tablet 300 mg
Study: NCT06558422
Drug: Growth Hormone, Human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.
Study: NCT06018337
Drug: DB-1303/BNT323
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT06018337
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral
Study: NCT04970992
Drug: DZ-002
Approvals — FDA: no, EMA: no, PMDA: no
Description: DZ-002 Injection